Donor-cell myelodysplastic syndrome developing 13 years after marrow grafting for aplastic anemia

Irén Haltrich, Judit Müller, Judit Szabó, Gábor Kovács, Rozália Kóos, Anna Poros, Matild Dobos, György Fekete

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Donor-cell-derived hematopoietic malignancy is a rare event after bone marrow transplantation. Most cases in the literature occurred within the first year. We present a rare case of a female patient who had a bone marrow transplant for severe aplastic anemia (SAA) at the age of two and a half years from her human leukocyte antigen-identical brother. She developed a myelodysplastic syndrome (refractory cytopenia with multilineage dysplasia) 12 years later. Initially, the malignant clone was of recipient origin, but within several months, progression to a clinically more aggressive refractory anemia with excess blasts (RAEB) was accompanied by the outgrowth of a new clone of donor origin. In this report we provide evidence proving that the patient's final malignant clone arose in donor cells: cytogenetic analysis of the marrow showed a male karyotype and a t(3;21)(q26;q21) in all 62 metaphases analyzed. Interphase fluorescence in situ hybridization showed that all identifiable cells contained the Y chromosome. We conclude that donor-cell-derived hematopoietic malignancy after bone marrow transplantation can occur even after many years. We believe that the 13 years that elapsed between the transplant and the development of RAEB in our case represent the longest latency period in the literature.

Original languageEnglish
Pages (from-to)124-128
Number of pages5
JournalCancer Genetics and Cytogenetics
Volume142
Issue number2
DOIs
Publication statusPublished - Apr 15 2003

Fingerprint

Aplastic Anemia
Myelodysplastic Syndromes
Bone Marrow
Tissue Donors
Refractory Anemia with Excess of Blasts
Clone Cells
Hematologic Neoplasms
Bone Marrow Transplantation
Transplants
Y Chromosome
Cytogenetic Analysis
Interphase
Metaphase
HLA Antigens
Fluorescence In Situ Hybridization
Karyotype
Siblings

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Donor-cell myelodysplastic syndrome developing 13 years after marrow grafting for aplastic anemia. / Haltrich, Irén; Müller, Judit; Szabó, Judit; Kovács, Gábor; Kóos, Rozália; Poros, Anna; Dobos, Matild; Fekete, György.

In: Cancer Genetics and Cytogenetics, Vol. 142, No. 2, 15.04.2003, p. 124-128.

Research output: Contribution to journalArticle

Haltrich, Irén ; Müller, Judit ; Szabó, Judit ; Kovács, Gábor ; Kóos, Rozália ; Poros, Anna ; Dobos, Matild ; Fekete, György. / Donor-cell myelodysplastic syndrome developing 13 years after marrow grafting for aplastic anemia. In: Cancer Genetics and Cytogenetics. 2003 ; Vol. 142, No. 2. pp. 124-128.
@article{4297f5a4920d477da03413cfa5228b31,
title = "Donor-cell myelodysplastic syndrome developing 13 years after marrow grafting for aplastic anemia",
abstract = "Donor-cell-derived hematopoietic malignancy is a rare event after bone marrow transplantation. Most cases in the literature occurred within the first year. We present a rare case of a female patient who had a bone marrow transplant for severe aplastic anemia (SAA) at the age of two and a half years from her human leukocyte antigen-identical brother. She developed a myelodysplastic syndrome (refractory cytopenia with multilineage dysplasia) 12 years later. Initially, the malignant clone was of recipient origin, but within several months, progression to a clinically more aggressive refractory anemia with excess blasts (RAEB) was accompanied by the outgrowth of a new clone of donor origin. In this report we provide evidence proving that the patient's final malignant clone arose in donor cells: cytogenetic analysis of the marrow showed a male karyotype and a t(3;21)(q26;q21) in all 62 metaphases analyzed. Interphase fluorescence in situ hybridization showed that all identifiable cells contained the Y chromosome. We conclude that donor-cell-derived hematopoietic malignancy after bone marrow transplantation can occur even after many years. We believe that the 13 years that elapsed between the transplant and the development of RAEB in our case represent the longest latency period in the literature.",
author = "Ir{\'e}n Haltrich and Judit M{\"u}ller and Judit Szab{\'o} and G{\'a}bor Kov{\'a}cs and Roz{\'a}lia K{\'o}os and Anna Poros and Matild Dobos and Gy{\"o}rgy Fekete",
year = "2003",
month = "4",
day = "15",
doi = "10.1016/S0165-4608(02)00804-X",
language = "English",
volume = "142",
pages = "124--128",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Donor-cell myelodysplastic syndrome developing 13 years after marrow grafting for aplastic anemia

AU - Haltrich, Irén

AU - Müller, Judit

AU - Szabó, Judit

AU - Kovács, Gábor

AU - Kóos, Rozália

AU - Poros, Anna

AU - Dobos, Matild

AU - Fekete, György

PY - 2003/4/15

Y1 - 2003/4/15

N2 - Donor-cell-derived hematopoietic malignancy is a rare event after bone marrow transplantation. Most cases in the literature occurred within the first year. We present a rare case of a female patient who had a bone marrow transplant for severe aplastic anemia (SAA) at the age of two and a half years from her human leukocyte antigen-identical brother. She developed a myelodysplastic syndrome (refractory cytopenia with multilineage dysplasia) 12 years later. Initially, the malignant clone was of recipient origin, but within several months, progression to a clinically more aggressive refractory anemia with excess blasts (RAEB) was accompanied by the outgrowth of a new clone of donor origin. In this report we provide evidence proving that the patient's final malignant clone arose in donor cells: cytogenetic analysis of the marrow showed a male karyotype and a t(3;21)(q26;q21) in all 62 metaphases analyzed. Interphase fluorescence in situ hybridization showed that all identifiable cells contained the Y chromosome. We conclude that donor-cell-derived hematopoietic malignancy after bone marrow transplantation can occur even after many years. We believe that the 13 years that elapsed between the transplant and the development of RAEB in our case represent the longest latency period in the literature.

AB - Donor-cell-derived hematopoietic malignancy is a rare event after bone marrow transplantation. Most cases in the literature occurred within the first year. We present a rare case of a female patient who had a bone marrow transplant for severe aplastic anemia (SAA) at the age of two and a half years from her human leukocyte antigen-identical brother. She developed a myelodysplastic syndrome (refractory cytopenia with multilineage dysplasia) 12 years later. Initially, the malignant clone was of recipient origin, but within several months, progression to a clinically more aggressive refractory anemia with excess blasts (RAEB) was accompanied by the outgrowth of a new clone of donor origin. In this report we provide evidence proving that the patient's final malignant clone arose in donor cells: cytogenetic analysis of the marrow showed a male karyotype and a t(3;21)(q26;q21) in all 62 metaphases analyzed. Interphase fluorescence in situ hybridization showed that all identifiable cells contained the Y chromosome. We conclude that donor-cell-derived hematopoietic malignancy after bone marrow transplantation can occur even after many years. We believe that the 13 years that elapsed between the transplant and the development of RAEB in our case represent the longest latency period in the literature.

UR - http://www.scopus.com/inward/record.url?scp=0345269218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345269218&partnerID=8YFLogxK

U2 - 10.1016/S0165-4608(02)00804-X

DO - 10.1016/S0165-4608(02)00804-X

M3 - Article

C2 - 12699888

AN - SCOPUS:0345269218

VL - 142

SP - 124

EP - 128

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 2

ER -